PURPOSE OF THIS RESEARCH: The Epworth Centre for Innovation in Mental Health (ECIMH) is investigating a new treatment for people with Alzheimer's disease. Our research is examining whether transcranial magnetic stimulation (TMS) can improve the cognitive symptoms of mild to moderate Alzheimer's disease such as memory and thinking difficulties.
WHAT IS TRANSCRANIAL MAGNETIC STIMULATION (TMS)? TMS is a form of non-invasive brain stimulation which uses a magnetic pulse to stimulate brain cells. A coil is placed on your head whilst you are seated comfortably in a chair, with the magnetic field increasing activity in the cells underneath the coil. TMS has been used for over 20 years in the treatment of depression. It has been shown to be a safe and effective treatment for that condition. We are now testing its use in the treatment of Alzheimer's disease. You will be randomly selected to receive either active or placebo (inactive) TMS. If you were randomised to the placebo group you will be offered active stimulation at the end of the follow-up period (3 or 6 months).
WHO IS ELIGIBLE TO PARTICIPATE?
- Men and women, aged 50 to 95 years
- With a diagnosis of mild to moderate Alzheimer's disease
- Interested in participating
For more information about the Alzheimer's clinical trials, contact: Dr Melanie Emonson Phone: (03) 9805 4346 (firstname.lastname@example.org) or Ms Veronika Simic Phone: (03) 9805 4151 (email@example.com).
This study has received ethics approval from the Alfred Human Research Ethics Committee, Project Number 372/15. Governance Approval has been provided by Epworth HealthCare, EH2018-386.